Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration

Inclusion Criteria: * Patients presenting with choroidal neovascular membrane secondary to causes other than AMD or patients with Pigment epithelial detachments secondary to AMD where there is demonstrated progression of the disease. * Total lesion area \< 12 disc areas. * Total area of CNV within the lesion must be \> 50% of total lesion area in the first category of recruits, but not in those with PEDs. * Best corrected visual acuity of 20/40 to 20/320 in the study eye. * Willing and able to give informed consent Exclusion Criteria: * Prior treatment in the study eye with, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy or other anti VEGF treatments. * History of submacular surgery or other surgical intervention in the study eye, glaucoma filtration surgery, corneal transplant surgery, * Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month preceding baseline, * Extracapsular extraction of cataract with phacoemulsification within three months preceding baseline, or a history of post-operative complications within the last 12 months preceding baseline in the study eye (uveitis, cyclitis, etc.), * History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication), * Aphakia with absence of the posterior capsule in the study eye, * Active intraocular inflammation (grade trace or above) in the study ey…